Grifols (NASDAQ:GRFS) was upgraded by equities researchers at HSBC from a “reduce” rating to a “hold” rating in a note issued to investors on Wednesday, March 14th.
Other analysts have also recently issued research reports about the company. ValuEngine upgraded Grifols from a “hold” rating to a “buy” rating in a report on Friday, February 2nd. BidaskClub upgraded Grifols from a “hold” rating to a “buy” rating in a report on Wednesday, January 10th. Zacks Investment Research upgraded Grifols from a “sell” rating to a “hold” rating in a report on Thursday, January 4th. UBS cut Grifols from an “outperform” rating to a “market perform” rating in a report on Friday, November 24th. Finally, Morgan Stanley decreased their price target on Grifols from $23.00 to $22.00 and set an “underweight” rating on the stock in a report on Thursday, March 1st. Three research analysts have rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company. Grifols has a consensus rating of “Hold” and an average price target of $22.50.
Shares of GRFS stock traded down $0.26 during trading hours on Wednesday, hitting $20.22. 714,116 shares of the company’s stock were exchanged, compared to its average volume of 588,475. The company has a debt-to-equity ratio of 1.62, a quick ratio of 1.35 and a current ratio of 3.01. The stock has a market capitalization of $13,984.21, a PE ratio of 18.38, a PEG ratio of 1.30 and a beta of 1.19. Grifols has a 52 week low of $18.79 and a 52 week high of $25.18.
Institutional investors have recently bought and sold shares of the stock. Lenox Wealth Management Inc. boosted its holdings in Grifols by 8,372.9% in the third quarter. Lenox Wealth Management Inc. now owns 5,931 shares of the biotechnology company’s stock valued at $129,000 after acquiring an additional 5,861 shares during the last quarter. First Republic Investment Management Inc. acquired a new position in Grifols in the third quarter valued at about $203,000. Dean Capital Investments Management LLC acquired a new position in Grifols in the fourth quarter valued at about $214,000. Pitcairn Co. acquired a new position in Grifols in the fourth quarter valued at about $228,000. Finally, Dowling & Yahnke LLC acquired a new position in Grifols in the fourth quarter valued at about $327,000. Institutional investors and hedge funds own 22.26% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/07/hsbc-upgrades-grifols-sa-barcelona-grfs-to-hold.html.
Grifols Company Profile
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.
Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.